|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096890 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-08 11:15:32 |
|
注册时间: Date of Registration: |
2025-02-08 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于MRI正常成人眼球突出度参考范围的初步建立 |
|
Public title: |
A Preliminary Establishment on The Reference Range of Exophthalmos of Normal Adult based on MRI |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于MRI正常成人眼球突出度参考范围的初步建立 |
|
Scientific title: |
A Preliminary Establishment on The Reference Range of Exophthalmos of Normal Adult based on MRI |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
许祖星 |
研究负责人: |
吕朝晖 |
|
Applicant: |
Zuxing Xu |
Study leader: |
Zhaohui Lyu |
|
申请注册联系人电话: Applicant telephone: |
+86 177 2695 4030 |
研究负责人电话:
Study leader's |
+86 186 1011 1788 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Xuzuxing_97@163.com |
研究负责人电子邮件: Study leader's E-mail: |
metabolism301@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
28 Fuxing Road, Haidian District, Beijing |
Study leader's address: |
28 Fuxing Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院 |
||
|
Applicant's institution: |
Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院 |
||
|
Affiliation of the Leader: |
Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2023-689-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-11-16 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
28 Fuxing Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
Xuzuxing_97@163.com |
|
研究实施负责(组长)单位: |
中国人民解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Medical Center Of Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究者自发课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Independent Inveatigatior-Initiated Trial |
||||||||||||||||||||||
|
研究疾病: |
正常成人 |
||||||||||||||||||||||
|
Target disease: |
Normal Adult |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机抽样 |
||||||||||||||||||||||
|
Study design: |
Randomly Sampling |
||||||||||||||||||||||
|
研究目的: |
主要目的:通过MRI准确测量正常成人的眼球突出度,初步建立正常成人眼球突出度参考范围,避免既往因Hertel突眼计、检查者主观能力等引起的误差。 次要目的:增加临床医生对正常突眼度的认识,提高对眼球突出的诊断准确性,帮助评估眼病情况及指导诊治 |
||||||||||||||||||||||
|
Objectives of Study: |
Main objective: To preliminarily establish the reference range of exophthalmometric values of normal adult, based on measuring accurately through MRI, avoiding errors caused by Hertel exophthalmometry and the subjective ability of the examiners. Secondary objective: To increase the awareness of clinical doctors about normal exophthalmos, improve the diagnostic accuracy of exophthalmos, and help evaluate the conditions of eye diseases and guide diagnosis and treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
扫描眼眶 Ax T2WI IDEAL序列 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Scan orbital sequence Ax T2WI IDEAL |
||||||||||||||||||||||
|
纳入标准: |
1.年龄≥18周岁,男女不限; 2.能够理解试验的目的,自愿参与接受检查并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria are as follows: 1. Age >= 18 years old, regardless of gender; 2. Able to understand the purpose of the experiment, voluntarily participate in the examination and sign an informed written consent. |
||||||||||||||||||||||
|
排除标准: |
1.眼部曾经进行过手术; 2.有眼部外伤史、眶周疾病、眶内肿物; 3.可能导致炎症性眼球突出的疾病,如眼眶蜂窝织炎、全眼球炎、IgG4相关性眼病; 4.甲状腺相关性眼病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of surgery on the eyes before; 2. History of eye trauma, periorbital diseases, and intraorbital tumors; 3. Diseases that may cause inflammatory exophthalmos, such as orbital cellulitis, panophthalmitis, and IgG4 related ophthalmic disease; 4. Thyroid associated Ophthalmopathy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-12-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-16 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究设置1个组别,采用单纯随机抽样,按受检者在MRI机房报道时间先后排序编号,并根据计算机生成随机数抽取。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study sets up one group and uses simple random sampling. The numbers were sorted according to the time when the subjects register in the MRI room. Select subjects based on the results of computer-generated random numbers. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心 https://ngdc.cncb.ac.cn/gsub/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |